Chemical Structure : Elacytarabine
CAS No.:
188181-42-2
Elacytarabine
(CP-4055;CP4055;ELACYT)
Catalog No.: PC-35560Not For Human Use, Lab Use Only.
Elacytarabine (CP-4055, CP4055, ELACYT) is a fatty acid derivative of cytarabine with potential antineoplastic activity.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
Elacytarabine (CP-4055, CP4055, ELACYT) is a fatty acid derivative of cytarabine with potential antineoplastic activity; CP-4055 is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, CP-4055 shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine.
Chemotherapeutic Agents
Phase 2 Clinical
Physicochemical Properties
|
M.Wt
|
507.672
|
|
Formula
|
C27H45N3O6
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20 °C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80 °C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate
|
References
1. Adams DJ, et al. Leuk Lymphoma. 2008 Apr;49(4):786-97.
2. Rubas W, et al. Int J Cancer. 1986 Jan 15;37(1):149-54.
3. Pignata S, et al. Cancer Chemother Pharmacol. 2011 Nov;68(5):1347-53.
4. Giles FJ, et al. Leukemia. 2012 Jul;26(7):1686-9.
Contact Us
sales@probechem.com
